Skip to main content
Premium Trial:

Request an Annual Quote

Fluidigm Raises $5M

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Fluidigm, which refiled for an initial public offering last month, disclosed it has raised $5 million in an offering this month.

In a document filed on Thursday with the US Securities and Exchange Commission, the South San Francisco, Calif., microfluidic chip and instrument firm disclosed the raise was done through an offering of debt; options, warrants, or other rights to acquire another security; and securities to be acquired upon exercise of option, warrants, or other rights to acquire another security.

Fluidigm said the first date of the sale was Jan. 6, and $3,214 remains unsold from the offering. It did not disclose who the investors are.

The company refiled its IPO on Dec. 6. It has not provided a price range for its share or the anticipated number of shares it will offer. Fluidigm had previously filed for an IPO in 2008 but abandoned it later that year.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.